Skip to main content
SleepCited

Research Figures

153 figures from peer-reviewed research

All 5-HTP Apigenin Ashwagandha CBD GABA Holy Basil Iron Kava Lavender Magnesium Glycinate Melatonin Omega-3 Fatty Acids Passionflower Tryptophan Valerian Root Vitamin B6 Vitamin D Zinc
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 2
Figure 2

Interventions for insomnia in cancer patients and survivors-a comprehensive systematic review and …

Figure 1
Figure 1

Insomnia and Restless Leg Syndrome in Patients Undergoing Chronic Hemodialysis in Rafsanjan …

Figure 2
Figure 2

Insomnia and Restless Leg Syndrome in Patients Undergoing Chronic Hemodialysis in Rafsanjan …

Figure 1
Figure 1

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A …

Fig. 2 Risk of bias (RoB) summary: review authors’ judgments about each RoB item for each included study.
Figure 2

Fig. 2 Risk of bias (RoB) summary: review authors’ judgments about each RoB item for each included study.

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A …

Figure 3
Figure 3

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A …

Figure 4
Figure 4

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A …

Fig. 5 Forest plot comparing efficacy of melatonin over control in total sleep time in children with ASD. ASD, autism spectrum disorder.
Figure 5

Fig. 5 Forest plot comparing efficacy of melatonin over control in total sleep time in children with ASD. ASD, autism spectrum disorder.

Efficacy of Melatonin for Insomnia in Children with Autism Spectrum Disorder: A …

Figure 1
Figure 1

Sleep-promoting activity of amylase-treated Ashwagandha (Withania somnifera L. Dunal) root extract via …

Figure 4
Figure 4

Sleep-promoting activity of amylase-treated Ashwagandha (Withania somnifera L. Dunal) root extract via …

Figure 5
Figure 5

Sleep-promoting activity of amylase-treated Ashwagandha (Withania somnifera L. Dunal) root extract via …

Figure. 1. Its shows the degradation mechanism of feather keratin. The feather keratin is a type of b-keratin and has a lot of disulfide bonds. There are 2 steps in the process of keratin breaking down: denaturation and hydrolyzation (Wang et al., 2023).
Figure 1

Figure. 1. Its shows the degradation mechanism of feather keratin. The feather keratin is a type of b-keratin and has a lot of disulfide bonds. There are 2 steps in …

Molecular strategies to enhance the keratinase gene expression and its potential implications …

Figure. 2. The efficiency and performance in poultry compared with traditional and keratinase supplemented diet.
Figure 2

Figure. 2. The efficiency and performance in poultry compared with traditional and keratinase supplemented diet.

Molecular strategies to enhance the keratinase gene expression and its potential implications …

Figure. 3. Propeptide assisted folding pathway. The expression of keratinase can be increased by accelerating the process of enzyme maturation by altering specific locations of the prepeptide, which in turn changes the protein folding rate.
Figure 3

Figure. 3. Propeptide assisted folding pathway. The expression of keratinase can be increased by accelerating the process of enzyme maturation by altering specific locations of the prepeptide, which in turn …

Molecular strategies to enhance the keratinase gene expression and its potential implications …

Figure. 4. Mechanism of synthesis & secretion of keratinase by Bacillus subtilis.
Figure 4

Figure. 4. Mechanism of synthesis & secretion of keratinase by Bacillus subtilis.

Molecular strategies to enhance the keratinase gene expression and its potential implications …

Figure 5. The main steps for producing keratinase in a different organism.
Figure 5

Figure 5. The main steps for producing keratinase in a different organism.

Molecular strategies to enhance the keratinase gene expression and its potential implications …

Fig. 1. Regional (A) R2, (B) R2*, (C) R2′ and (D) QSM values corrected for age and volume for healthy controls (blue) and RLS patients (red). CAU: Caudate, DEN: Dentate nuclei, PAL: Pallidum, PUT: Putamen, RN: Red nuclei, SN: Substantia Nigra, STN: Subtha
Figure 3

Fig. 1. Regional (A) R2, (B) R2*, (C) R2′ and (D) QSM values corrected for age and volume for healthy controls (blue) and RLS patients (red). CAU: Caudate, DEN: Dentate …

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Fig. 2. Flow Diagram of the systematic search for MRI studies of iron in RLS.
Figure 4

Fig. 2. Flow Diagram of the systematic search for MRI studies of iron in RLS.

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Figure 5
Figure 5

Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging.

Fig. 1. Brief mechanism of the clock genes.
Figure 1

Fig. 1. Brief mechanism of the clock genes.

Bipolar Disorder, Circadian Rhythm and Clock Genes.

Figure 1
Figure 1 Flowchart

Treatment algorithm for restless legs syndrome outlines the step-wise pharmacologic approach from initial dopamine agonist therapy through iron supplementation and alternative agents for refractory or augmentation cases.

Pharmacologic Treatment of Restless Legs Syndrome.

In mild cases of RLS, dopamine agonist therapy can be continued after augmentation by dividing or advancing the dose before symptom onset while ensuring that the maxi-
Figure 2 Diagram

In mild RLS cases, dopamine agonist therapy management after augmentation is illustrated, showing dose adjustment strategies and transition to alternative medications including alpha-2-delta ligands and opioids for resistant cases.

Pharmacologic Treatment of Restless Legs Syndrome.

Figure 2
Figure 2

Biodegradation and Subsequent Toxicity Reduction of Co-contaminants Tribenuron Methyl and Metsulfuron Methyl …

Figure 4
Figure 4

Biodegradation and Subsequent Toxicity Reduction of Co-contaminants Tribenuron Methyl and Metsulfuron Methyl …

Page 3 of 7